<DOC>
	<DOCNO>NCT02372695</DOCNO>
	<brief_summary>To provide evidence base prospectives potential benefit effect paricalcitol , analog vitamin D , prevention / retardation progression neoangiogenesis ( vessel ) , atherosclerosis vascular calcification .</brief_summary>
	<brief_title>Effect Paricalcitol Over Vessel Wall</brief_title>
	<detailed_description>Providing prospective result base evidence potential beneficial effect paricalcitol , analogue vitamin D prevention / delay progression neoangiogenesis ( vessel ) , atherosclerosis vascular calcification .</detailed_description>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Patients age 50 75 year . Chronic kidney disease stage 5 D 45 No D calculate glomerular filtration rate ( MDRD ) . Concentration intact parathyroid hormone ( iPTH ) : 150400 pg/ml . Plasma concentration 25 ( OH ) vitamin D &lt; 30 ng/ml . Without vitamin D supplementation 3 month study . Serum P &gt; 3.8 mg / dl . Serum Ca &gt; 9.8 mg / dl . No history cardiovascular event ( angina myocardial infarction , stroke , peripheral arterial disease ) . No exclusion criterion use contrast . Allergic reaction sulfur hexafluoride . Recent unstable cardiac symptom . Patients recent coronary intervention ( &lt; 7 day ) Patients class III IV heart failure severe arrhythmia . Severe pulmonary hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>